Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04246086
Title A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len) or Glofitamab + Len With or Without Obinutuzumab; and Evaluating the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With R/R Follicular Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

follicular lymphoma

Therapies

Tocilizumab

Obinutuzumab

Lenalidomide + Obinutuzumab + RO7082859

Lenalidomide + RO7082859

Lenalidomide + Mosunetuzumab

Age Groups: senior | adult
Covered Countries USA | FRA | ESP


No variant requirements are available.